Drug and device firm Neoprobe Inc. has nominated two new directors who will stand for election at the company’s annual shareholder meeting in July.
One nominee is Brendan Ford, a managing director at Columbus, Ohio-based private equity firm Talisman Capital Partners, according to a statement from Dublin, Ohio-based Neoprobe. Prior to Talisman, Ford was an executive vice president of corporate development for Cardinal Health.
The other nominee is Dr. Eric Rowinsky, an independent consultant. Rowinsky was previously chief medical officer for ImClone Systems Inc., a New Jersey-based cancer drug developer.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
If elected at the July 16 shareholder meeting, the two nominees would replace retiring directors Reuven Avital and J. Frank Whitley Jr.
Neoprobe executives said last month that the company plans this summer to file for regulatory approval of its cancer-detecting drug, Lymphoseek.
